Family Campaigns for NHS to Approve New Cancer Treatment After Positive Trial Results
The family of Huw Jones, who tragically passed away from bile duct cancer, is leading a heartfelt campaign urging the National Health Service (NHS) to approve a promising new treatment called zanidatamab. This targeted therapy significantly enhanced Jones's quality of life, allowing him to spend precious time with his family following his diagnosis.
Huw Jones's Journey with Zanidatamab
Huw Jones, a resident of north Wales, was diagnosed with stage 4 cholangiocarcinoma, an aggressive form of bile duct cancer with notoriously poor survival rates. In January 2025, he began taking zanidatamab as part of a clinical trial. The treatment proved transformative, enabling him to enjoy a year of improved health after the birth of his son, which his family describes as offering a "normal life" during a challenging period.
NICE Review and Wider Implications
The National Institute for Health and Care Excellence (NICE), the NHS's spending watchdog, initially rejected zanidatamab for widespread use due to insufficient evidence. However, it is scheduled to reassess further clinical data in March 2026, raising hopes for broader availability. This decision could impact many patients with HER2-positive bile duct cancer, a subtype that often has limited treatment options.
Success Stories and Patient Advocacy
Another notable patient, NHS surgeon Gareth Honeybone, also participated in a clinical trial for zanidatamab and experienced remarkable benefits. Recent scans indicate that his tumour is no longer visible, showcasing the treatment's potential efficacy. Charities and patient advocates emphasise that zanidatamab not only extends life but also improves quality of life, offering a beacon of hope for those battling this devastating disease.
As the campaign gains momentum, families and medical professionals are calling for swift approval to ensure more patients can access this innovative therapy, potentially changing outcomes for aggressive cancers.
